Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Andrew Cummings
March 4, 2017

(NYSE:VRX) was among the mix trends movers as shares jumped up 1.18% to $13.75.

In the last trading session, The Company traded 18.45 Million shares.

Several other research firms have also recently issued reports on VRX. Riggs Asset Managment Co. Fosun International Ltd increased its stake in Valeant Pharmaceuticals Intl by 59.8% in the second quarter. The Stock Market opened sessions at 13.9 and closed at 13.75. Stock has got OUTPERFORM rating from 1 analyst of Thomson Reuters, 11 analysts given HOLD rating to the stock and 4 given UNDERPERFORM rating.

The company shows its Return on Assets (ROA) value of -4.7%. Convector Capital Management LP increased its stake in shares of Valeant Pharmaceuticals Intl by 53.6% in the second quarter.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Steinberg and Chris Schott have a yearly average return of 2.3% and 4.1% respectively. Morgan Stanley raised its stake in shares of Valeant Pharmaceuticals Intl by 241.6% in the third quarter.

A number of large investors have recently modified their holdings of the company. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company's stock worth $141,000 after buying an additional 3,361 shares in the last quarter. (NYSE:VRX) to Hold with no specific Price Target. The Relative Volume value measured for Valeant Pharmaceuticals International, Inc. The company has a 50-day moving average of $14.94 and a 200 day moving average of $19.85. The firm's market capitalization is $5.33 billion.

Analysts estimated $1.21/share for the previous Quarter, where Valeant Pharmaceuticals International, Inc. The company beat the analyst EPS Estimate with the difference of $-0.2. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. The business's revenue for the quarter was down 11.0% compared to the same quarter previous year. The firm's revenue for the quarter was down 12.9% on a year-over-year basis.

While looking at the Stock's Performance, Valeant Pharmaceuticals International, Inc. now shows a Weekly Performance of -17.07%, where Monthly Performance is -0.22%, Quarterly performance is -19.87%, 6 Months performance is -54.55% and yearly performance percentage is -79.62%.

The 16 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 20.00, with a high estimate of 55.00 and a low estimate of 9.00. The company has an average rating of "Hold" and a consensus price target of $28.48. Finally, Morgan Stanley reiterated an overweight rating and issued a $42.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, November 2nd. Mizuho restated a neutral rating and issued a $25.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, November 1st. It has been recommended as "Buy Opinions" from 3 and 0 suggested "Sell Thoughts" for the stock.

In other Valeant Pharmaceuticals Intl news, Director Pershing Square Capital Manage sold 3,476,690 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $14.85, for a total value of $51,628,846.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Ross bought 5,000 shares of the business's stock in a transaction on Wednesday, December 14th. The average numbers of shares are traded in a security per day, during the recent 3-month period. Following the completion of the acquisition, the director now owns 26,822 shares of the company's stock, valued at approximately $395,088.06. The disclosure for this sale can be found here.

Valeant Pharmaceuticals International, Inc. on 02/28/2017 reported its EPS as $1.55 with the analysts projecting the EPS of the stock as $1.75. The Emerging Markets consists of branded generic pharmaceutical and branded pharmaceuticals; over-the-counter and medical device products.

Other reports by iNewsToday